for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aevi Genomic Medicine Inc

GNMX.OQ

Latest Trade

0.17USD

Change

-0.01(-5.08%)

Volume

95,781

Today's Range

0.17

 - 

0.19

52 Week Range

0.15

 - 

1.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.18
Open
0.19
Volume
95,781
3M AVG Volume
35.84
Today's High
0.19
Today's Low
0.17
52 Week High
1.40
52 Week Low
0.15
Shares Out (MIL)
64.77
Market Cap (MIL)
11.01
Forward P/E
-0.35
Dividend (Yield %)
--

Latest Developments

More

Aevi Genomic Medicine Received Notice From Nasdaq Notifying Co Had Not Regained Compliance With Minimum Bid Price Requirement

Aevi Genomic Medicine Enters Into License Agreement With Astrazeneca For Anti-IL-18 Antibody

Aevi Genomic Medicine Inc Says Chief Financial Officer Brian Piper Resigns

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aevi Genomic Medicine Inc

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .

Industry

Biotechnology & Drugs

Contact Info

435 Devon Park Dr Ste 715

+1.610.2544201

http://www.aevigenomics.com/

Executive Leadership

Sol J. Barer

Non-Executive Chairman of the Board

Michael F. Cola

President, Chief Executive Officer, Director

Michael McInaw

Interim Chief Financial Officer

Garry A. Neil

Chief Scientific Officer

Matthew D. Bayley

Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.190

2017

-0.830

2018

-0.500

2019(E)

-0.450
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
33.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-286.25
Return on Equity (TTM)
-184.37

Latest News

BRIEF-Aevi Genomic Medicine Q1 Loss Per Share $0.15

* AEVI GENOMIC MEDICINE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aevi Genomic Medicine Files For Mixed Shelf Of Up To $50 Mln

* AEVI GENOMIC MEDICINE INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source text: (https://bit.ly/2IjWI5B) Further company coverage:

BRIEF-Aevi Genomic Medicine Files Prospectus Supplement Related To Offering Of Common Stock

* AEVI GENOMIC MEDICINE INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF UP TO $20 MILLION CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2wHEyJD) Further company coverage:

BRIEF-Aevi Genomic Medicine Reports Q4 Loss Per Share $0.13

* AEVI GENOMIC MEDICINE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co

* AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD

BRIEF-Aevi Genomic Medicine Files For Resale Of Up To 26.2 Mln Shares Of Co's Common Stock By Selling Stockholders

* AEVI GENOMIC MEDICINE INC FILES FOR RESALE OF UP TO 26.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - http://bit.ly/2kEddlX Further company coverage:

BRIEF-Aevi Genomic Medicine Announces New Appointment To Its Board Of Directors

* AEVI GENOMIC MEDICINE ANNOUNCES NEW APPOINTMENT TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Aevi Genomic Medicine Q3 loss per share $0.23

* Aevi Genomic Medicine reports third quarter 2017 financial results

BRIEF-Aevi Genomic Medicine announces private placement

* Aevi Genomic Medicine announces agreement for $28 million private placement

BRIEF-Aevi Genomic Medicine reports Q2 loss per share of $0.22

* Aevi Genomic Medicine reports second quarter 2017 financial results

BRIEF-Aevi Genomic Medicine reprts qtrly loss per share of $0.22

* Qtrly diluted loss per share $0.22 Source text for Eikon: Further company coverage:

BRIEF-Adage Capital Partners report a passive stake of 5.56 pct in Aevi Genomic Medicine,

* Adage Capital Partners reports a passive stake of 5.56 pct in Aevi Genomic Medicine, as of May 24 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Aevi Genomic Medicine posts Q1 loss per share $0.29

* Aevi Genomic Medicine announces plans to initiate Phase 2 clinical trial to confirm genetic responders to AEVI-001 and first quarter 2017 operating results

BRIEF-Philip Harper reports 13.6 pct passive stake in Aevi Genomic Medicine

* Philip R. Harper reports 13.6 percent passive stake in Aevi Genomic Medicine Inc as of March 20 - sec filing Source text : http://bit.ly/2olmBsg Further company coverage:

BRIEF-Aevi Genomic Medicine provides top-line results from saga trial

* Aevi Genomic Medicine provides top-line results from the saga trial of aevi-001

BRIEF-Aevi Genomic Medicine reports Q4 loss per share $0.23

* Aevi Genomic Medicine reports fourth quarter and full year 2016 financial results and provides business update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up